An observational study in Wilson Disease, sponsored by Fondation Ophtalmologique Adolphe de Rothschild. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Fondation Ophtalmologique Adolphe de Rothschild · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Hepatolenticular Degeneration with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Hepatolenticular Degeneration · France.
Among the 17 studies in Hepatolenticular Degeneration with a site in France, this one is one of 3 that started in 2023, is one of 6 observational ones, and was the 12th registered.
80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.
Browse Hepatolenticular Degeneration studies →8 of the 17 studies in Hepatolenticular Degeneration with a site in France are open now. Recruiting first, the newest first:
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 7+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 12+ · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 6–70
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 18+
Orphalan · Sites in France, Belgium, Germany and 4 more countries
Ages 12+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 72 across 35 observational studies indexed under Hepatolenticular Degeneration.
Median enrollment 40 across the 11 interventional studies, 150 across the 6 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 17 have an industry lead sponsor. The 7 most frequent:
Fondation Ophtalmologique Adolphe de Rothschild is the lead sponsor of 316 studies on the registry; 78 are open to participants now.
Fondation Ophtalmologique Adolphe de Rothschild has 7 studies filed under Hepatolenticular Degeneration — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatolenticular Degeneration with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06430359Hospices Civils de LyonCircadian Variation of Urinary Copper Excretion in Wilson Disease Patients | 2027-02-10 |
| NCT05183165Fondation Ophtalmologique Adolphe de RothschildDescription of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease | 2027-03 |
| NCT05444127Fondation Ophtalmologique Adolphe de RothschildOral Health and Wilson's Disease: SOMAWI | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies in Hepatolenticular Degeneration with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients with Wilson disease have poorer dental and periodontal health and a have lower oral quality of life than control patients. Patients with a neurological form would also more frequently present limitations in the function of the masticatory apparatus. Systemic treatments for Wilson disease are associated with lesions of the oral mucosa. Analysis of copper level in saliva could testify to the effectiveness of copper depletion in treated patients The main objective is to compare the state of dental health between: patients with Wilson disease in the hepatic form and patients with the neurological form, and a population of controls.
The comparaison between the three groups is based on evaluation criteria wich is CAOD index of caries severity (developed by Klein and Palmer in 1940) counting the number of permanent teeth with caries (evolving to include non-cavitary caries) (C), absent due to caries (A) and filled (O) in an individual. The maximum score is 28 (third molars are not taken into account). The index is obtained from clinical examination and panoramic dental imaging.
The recruitment of Wilson patients will be done in the coordinating center of the CRMR Wilson at the Fondation A de Rothschild Hospital. Control patients matched in age and sex will be identified among patients consulting in the oral medicine department of Charles Foix Hospital. Posters will be placed in the waiting room to inform patients of the existence of the study and promote recruitment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For cases:
For witnesses:
patients with hepatic form of Wilson disease and those with neurological form
Other: Saliva samples · Other: Questionnaire OHIP-14 · Other: Thorough dental examination
control population consulting in routine dental with panoramic dental imaging, outside of an emergency context
Other: Questionnaire OHIP-14 · Other: Thorough dental examination
A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
A saliva sample is added by research for all patients, as well as an oral quality of life questionnaire. For the witnesses, participation also entails the completion of the standardized oral examination (potentially longer than the assessment that would have been carried out as part of the treatment) and the administration of the oral quality of life questionnaire.
CAOD index of the severity of the caries impairment counting the number of permanent teeth decayed in an individual. The maximum score is 28 (third molars are not taken into account)
The index is obtained from clinical examination and panoramic dental imaging
Time frame: inclusion visit
Started May 2023 (actual). Primary completion is estimated for Aug 2027, 51 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Oct 2026 → Aug 2027 and completion Oct 2026 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hepatolenticular Degeneration →
Fondation Ophtalmologique Adolphe de Rothschild →